Wednesday, July 22, 2020, 5:00 PM – 6:00 PM ET

Recent Advances in Medical Oncology: Melanoma

Join us on Wednesday, July 22 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 CreditTM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.


Michael B Atkins, MD
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center
William M Scholl Professor and Vice-Chair, Department of Oncology
Professor of Medicine
Georgetown University Medical Center
Washington, DC

Jason J Luke, MD
Associate Professor and Director of the Cancer Immunotherapeutics Center
University of Pittsburgh Medical Center and Hillman Cancer Center
Pittsburgh, Pennsylvania

Professor Georgina Long, AO, BSc, PhD, MBBS
Co-Medical Director of Melanoma Institute Australia
Chair of Melanoma Medical Oncology and Translational Research
Melanoma Institute Australia and Royal North Shore Hospital
The University of Sydney
Sydney, Australia

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Merck.

Evolving Treatment Approaches for Patients with Localized or Locally Advanced Melanoma — Prof Long

  • Research supporting the FDA approvals of adjuvant nivolumab and pembrolizumab for patients with resected high-risk melanoma
  • Efficacy and safety outcomes from the Phase III COMBI-AD study evaluating dabrafenib/trametinib as adjuvant treatment for high-risk melanoma with a BRAF V600 tumor mutation after surgical resection; FDA-approved dose, schedule and indication for adjuvant dabrafenib/trametinib
  • Biologic rationale for the design of clinical trials combining EGFR- and VEGFR-targeted therapy; key findings from the Phase III RELAY study leading to the FDA approval of erlotinib in combination with ramucirumab for patients with previously untreated metastatic EGFR-mutant NSCLC; ramifications on practice and future clinical trial design
  • Clinical, biologic and practical factors influencing the decision to use an anti-PD-1 antibody versus dabrafenib/trametinib as adjuvant treatment for disease with a BRAF mutation
  • Ongoing clinical trials incorporating novel agents and immunotherapeutic approaches in the adjuvant and neoadjuvant settings

Integration of BRAF/MEK Inhibitors into the Management of Metastatic Melanoma with a BRAF Tumor Mutation — Jason J Luke, MD

  • Optimal management of metastatic melanoma with a BRAF tumor mutation; factors affecting the selection of a specific BRAF/MEK inhibitor combination
  • Molecular and pharmacologic similarities and differences among various BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib)
  • Clinical trial database supporting the use of BRAF/MEK inhibitor combination therapy in patients with metastatic melanoma
  • Incidence, prevention and management of side effects and toxicities associated with available BRAF/MEK inhibitor combinations
  • Biologic rationale for and available data with the combination of anti-PD-L1 and BRAF/MEK inhibitor therapies for patients with previously untreated BRAF V600 mutation-positive metastatic melanoma
  • Available data sets examining the use of targeted therapy after disease progression on an immune checkpoint inhibitor or vice versa; optimal sequencing for patients who are candidates for both of these approaches

Current and Future Role of Immune Checkpoint Inhibitors in the Management of Metastatic Melanoma, Including Those with CNS Metastases — Michael B Atkins, MD

  • Therapeutic decision-making for patients with BRAF wild-type metastatic disease; selection of anti-PD-1 monotherapy versus anti-PD-1/anti-CTLA-4 therapy
  • Optimal management of BRAF wild-type disease that has progressed on or after adjuvant immune checkpoint inhibitor therapy
  • Inter- and extracranial benefit rates in patients receiving the combination of nivolumab and ipilimumab in the Phase III CheckMate 204 trial; implications for therapeutic selection in patients with untreated brain metastases
  • Efficacy and safety data from the Phase I/II PIVOT-02 study leading to the FDA breakthrough therapy designation for bempegaldesleukin in combination with nivolumab for individuals with previously untreated metastatic melanoma
  • Biologic rationale for, published research findings with and ongoing investigation of other promising novel therapies (eg, relatlimab)

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

Learning Objectives

  • Identify patients after surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel these individuals regarding the risks and potential benefits of existing and recently approved systemic approaches.
  • Consider age, performance status and other disease-related factors to guide the selection of first- and later-line therapy for patients with metastatic BRAF wild-type melanoma.
  • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with a BRAF tumor mutation.
  • Recognize the recent FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with a BRAF tumor mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Identify adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize and/or manage side effects.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy, other immunotherapies) for patients with advanced melanoma, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr AtkinsAdvisory Committee: Arrowhead Pharmaceuticals, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Idera Pharmaceuticals Inc, Leads Biolabs, Merck, Novartis, PACT Pharma, Pfizer Inc, Pneuma Medical, Pyxis Oncology, Roche Laboratories Inc, Werewolf Therapeutics; Consulting Agreements: Agenus Inc, Apexigen, COTA, Immunocore, Iovance Biotherapeutics, Neoleukin Therapeutics, Third Rock Ventures; Contracted Research (to Institution): Bristol-Myers Squibb Company, Merck; Data and Safety Monitoring Board/Committee: Novartis, PACT Pharma; Ownership Interest: Pyxis Oncology, Werewolf Therapeutics. Prof LongConsultant Advisor: Aduro Biotech, Agena Bioscience Inc, Amgen Inc, Bristol-Myers Squibb Company, Highlight Therapeutics, Merck, Merck Sharp & Dohme Corp, Novartis, OncoSec Medical, Pierre Fabre, QBiotics Group, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Skyline Pharmaceuticals Inc. Dr LukeAdvisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Spring Bank Pharmaceuticals Inc, Tempest Therapeutics Inc; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, IDEAYA Biosciences, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, A GSK Company, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen Inc, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, Genentech, Immatics Biotechnologies GmbH, Immunocore, Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology; Paid Travel: Akrevia Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Ownership Interest: AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Tempest Therapeutics Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Merck.